Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 197

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

Open access
Zhu, Andrew X., Abrams, Thomas A., Miksad, Rebecca, Blaszkowsky, Lawrence S., Meyerhardt, Jeffrey A., Zheng, Hui, Muzikansky, Alona, Clark, Jeffrey W., Kwak, Eunice L., Schrag, Deborah, Jors, Kathryn R., Fuchs, Charles S., Iafrate, A. John, Borger, Darrell R., Ryan, David P. · 2011 · Cancer

Abstract

BACKGROUND: The phosphoinositide 3‐kinase/Akt/mammalian target of rapamycin pathway plays a critical role in the pathogenesis of hepatocellular carcinoma (HCC). We performed a single‐arm, phase 1/2 study of everolimus in patients with advanced HCC. METHODS: Patients with histologically confirmed measurable advanced HCC, 0‐2 prior regimens, and adequate hematologic, hepatic, and renal functions received everolimus at 5 mg/day or 10 mg/day orally (6 weeks/cycle). The primary end points were determination of a safe dosage of everolimus (phase 1) and progression‐free survival (PFS) at 24 weeks (phase 2). RESULTS: Twenty‐eight patients were enrolled and evaluable for efficacy and toxicity. No dose‐limiting toxicities were observed at the 5 mg/day (n = 3) or 10 mg/day (n = 6) dosage level in phase 1. Twenty‐five patients received everolimus at 10 mg/day. Grade 3‐4 adverse events included lymphopenia (n = 3), aspartate transaminase (n = 3), hyponatremia (n = 2), and 1 patient each with anemia, alanine transaminase, hyperglycemia, proteinuria, rash, and hypoxia. One patient (4%) had partial response (95% confidence interval [CI], 0.9%‐19.6%). The median PFS and overall survival were 3.8 months (95% CI, 2.1‐4.6) and 8.4 months (95% CI, 3.9‐21.1), respectively. The estimated PFS rate at 24 weeks was 28.6% (95% CI, 7.9%‐49.3%). CONCLUSION: Everolimus was well tolerated in patients with advanced HCC, and 10 mg/day was defined as the phase 2 dosage. Although the study did not proceed to the second stage of phase 2, preliminary antitumor activity was observed with everolimus in patients with advanced HCC, most of whom had prior systemic treatment. Cancer 2011. © 2011 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.26165

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

Metadata

Authors
Zhu, A. X., Abrams, T. A., Miksad, R., Blaszkowsky, L. S., Meyerhardt, J. A., Zheng, H., Muzikansky, A., Clark, J. W., Kwak, E. L., Schrag, D., Jors, K. R., Fuchs, C. S., Iafrate, A. J., Borger, D. R., & Ryan, D. P.
Venue
Cancer
Publisher
Wiley
Published
2011-04-27
Volume
117
Issue
22
Pages
5094-5102
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2165901246
Cited by
197
References
4
FWCI
16.90
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.